Scarica l'app Stockscreener
25.00
3.48%
0.84
Precedente Chiudi:
$24.16
Aprire:
$24.45
Volume 24 ore:
223.56K
Relative Volume:
2.17
Capitalizzazione di mercato:
$362.14M
Reddito:
$1.80M
Utile/perdita netta:
$1.76B
Rapporto P/E:
0.2107
EPS:
118.674
Flusso di cassa netto:
$-149.23M
1 W Prestazione:
+7.16%
1M Prestazione:
+9.36%
6M Prestazione:
+99.04%
1 anno Prestazione:
+92.46%
Intervallo 1D:
$24.00
$25.61
Intervallo di 1 settimana:
$22.40
$25.61
Portata 52W:
$10.80
$25.61
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Confronta INBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
25.00 | 345.77M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
How to monitor Inhibrx Biosciences Inc. with trend dashboardsAnalyst Downgrade & Long-Term Safe Investment Plans - Newser
Momentum Traders Eye Inhibrx Biosciences Inc. for Quick BounceJuly 2025 PreEarnings & Growth Focused Stock Reports - classian.co.kr
Inhibrx Biosciences Inc. Recovery Likely Here’s What Data ShowsWeekly Stock Analysis & Long-Term Investment Growth Plans - classian.co.kr
Quant Models Detect Momentum Reversal in Inhibrx Biosciences Inc.2025 Growth vs Value & Low Drawdown Investment Strategies - newsyoung.net
Inhibrx Biosciences Inc. stock outlook for YEARMarket Sentiment Report & Weekly Sector Rotation Insights - Newser
Backtesting results for Inhibrx Biosciences Inc. trading strategiesJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - Newser
How to forecast Inhibrx Biosciences Inc. trends using time seriesQuarterly Trade Review & High Win Rate Trade Tips - Newser
Analyzing drawdowns of Inhibrx Biosciences Inc. with statistical tools2025 Dividend Review & Verified Entry Point Signals - Newser
Is it too late to sell Inhibrx Biosciences Inc.2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Key resistance and support levels for Inhibrx Biosciences Inc.July 2025 Market Mood & Proven Capital Preservation Methods - Newser
Predicting Inhibrx Biosciences Inc. trend using moving averagesJuly 2025 Closing Moves & Consistent Income Trade Ideas - Newser
Published on: 2025-08-20 02:19:27 - Newser
How to build a dashboard for Inhibrx Biosciences Inc. stockQuarterly Performance Summary & Accurate Technical Buy Alerts - Newser
Is Inhibrx Biosciences Inc. trending in predictive chart modelsEarnings Overview Summary & Weekly Breakout Stock Alerts - Newser
Top chart patterns to watch in Inhibrx Biosciences Inc.Weekly Stock Report & Momentum Based Trading Ideas - Newser
How to integrate Inhibrx Biosciences Inc. into portfolio analysis tools2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
News impact scoring models applied to Inhibrx Biosciences Inc.Portfolio Update Report & Stepwise Trade Signal Guides - Newser
Inhibrx Biosciences Inc. stock prediction for this week2025 Buyback Activity & Safe Capital Growth Stock Tips - Newser
Using flow based indicators on Inhibrx Biosciences Inc.July 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Published on: 2025-08-19 05:33:15 - Newser
Short Covering May Lift Inhibrx Biosciences Inc. in Near Term2025 Technical Patterns & Entry Point Strategy Guides - kangso.co.kr
Inhibrx Biosciences Inc. Volume Confirms Breakout — Analysts Bullish2025 Year in Review & Weekly High Return Forecasts - Newser
Real time breakdown of Inhibrx Biosciences Inc. stock performanceWeekly Gains Summary & Technical Buy Zone Confirmations - Newser
Published on: 2025-08-18 02:46:49 - Newser
Sentiment analysis tools applied to Inhibrx Biosciences Inc.Trade Risk Report & AI Based Buy and Sell Signals - Newser
Reversal indicators forming on Inhibrx Biosciences Inc. stockJuly 2025 Fed Impact & Daily Market Momentum Tracking - Newser
What’s the recovery path for long term holders of Inhibrx Biosciences Inc.Earnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Inhibrx Biosciences Inc. stock trendline breakdown2025 Retail Activity & Verified Entry Point Signals - Newser
Visual trend scoring systems applied to Inhibrx Biosciences Inc.Trade Exit Summary & Safe Capital Growth Tips - Newser
Inhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Inhibrx Biosciences Inc. stock trend outlook and recovery path2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
Will Inhibrx Biosciences Inc. benefit from sector rotation2025 Price Targets & Fast Moving Stock Trade Plans - thegnnews.com
Inhibrx Biosciences Inc. stock momentum explainedJuly 2025 Patterns & Weekly Top Stock Performers List - Newser
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inhibrx Biosciences Inc Azioni (INBX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | Director |
Nov 20 '24 |
Buy |
14.19 |
37,500 |
532,204 |
69,843 |
| Lappe Mark | Chief Executive Officer |
Sep 12 '24 |
Buy |
15.05 |
26,963 |
405,793 |
692,511 |
| Lappe Mark | Chief Executive Officer |
Sep 16 '24 |
Buy |
17.13 |
13,037 |
223,324 |
705,548 |
| Vuori Kristiina MD | Director |
Sep 11 '24 |
Buy |
15.07 |
6,457 |
97,307 |
13,776 |
| Vuori Kristiina MD | Director |
Sep 10 '24 |
Buy |
15.00 |
179 |
2,685 |
7,319 |
| Lappe Mark | Chief Executive Officer |
Sep 06 '24 |
Buy |
15.29 |
26,000 |
397,540 |
647,548 |
| Lappe Mark | Chief Executive Officer |
Sep 09 '24 |
Buy |
15.21 |
9,500 |
144,495 |
657,048 |
| Lappe Mark | Chief Executive Officer |
Sep 10 '24 |
Buy |
15.19 |
8,500 |
129,115 |
665,548 |
| Lappe Mark | Chief Executive Officer |
Sep 03 '24 |
Buy |
15.81 |
20,000 |
316,263 |
165,000 |
| Lappe Mark | Chief Executive Officer |
Aug 29 '24 |
Buy |
14.03 |
10,000 |
140,300 |
135,000 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):